Manish Kumar Health, Pharma Proff, Prurigo Therapeutics Pipeline

Prurigo Therapeutics Pipeline Analysis 2018

Prurigo is a group of skin diseases characterised by intensely pruritic, and difficult to treat. There are two conditions associated with prurigo which includes nodular prurigo and papular prurigo. Nodular prurigo is characterized by symmetrical lesions usually on the distal limbs; while, papular prurigo represents smaller lesions which affect cape area.

Download the sample report at: https://www.pharmaproff.com/request-sample/1017

Prurigo is associated with other skin conditions such as atopic eczema, iron deficiency, thyroid disease, Hodgkin lymphoma, non-Hodgkin lymphoma, pregnancy, chronic renal failure, diabetes, drug abuse and spinal nerve damage. 

Corticosteroids, sedative anti-histamines, antibiotics, emollients, ciclosporin, azathioprine, thalidomide, neuropathic treatments and phototherapy are some of the standard treatments available for the prurigo. 

Trevi Therapeutics Inc. is a key player in the prurigo therapeutics pipeline arena, which is currently developing Nalbuphine ER, a small molecule which acts as an opioid receptor agonist. The company is also evaluating the product for the treatment of prurigo nodularis. Menlo Therapeutics Inc., and Kiniksa Pharmaceuticals Ltd. are some other players having prurigo therapeutics in their pipeline.

Manish Kumar cardiovascular disease, Health, Pharma Proff, Ventricular Arrhythmia Therapeutics

Ventricular Arrhythmia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results

Ventricular arrhythmia is a cardiovascular disease that is characterized by slow beats (bradycardia) and fast beats (tachycardia). Ventricular arrhythmia generally occurs in the lower chamber of the heart. 

Download the sample report at: https://www.pharmaproff.com/request-sample/1009

Ventricular fibrillation, ventricular tachycardia, and premature ventricular beats are the three types of ventricular arrhythmia observed in the patients. Among these, ventricular fibrillation is the most serious type and is characterized by irregular and uncontrollable beats.

Get the detailed analysis at: https://www.pharmaproff.com/report/ventricular-arrhythmia-therapeutics-pipeline-analysis

Premature ventricular contraction is characterized by irregular heartbeats, in which the ventricles contract too soon. Ventricular tachycardia is a type of arrhythmia in which the ventricles are no longer in control of the SA node. Huya Bioscience International is in the process of developing HBI-3000 as a multi-ion channel blocker for the treatment of ventricular arrhythmia. Also, ARMGO Pharma Inc. is in the process of developing ARM036 as a ryanodine receptor calcium release channel modulator for the treatment of this disease. 

Manish Kumar Galectin Inhibitor Therapeutics, Health, Pharma Proff

Galectin Inhibitor Therapeutics – Pipeline Analysis 2019

Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation.

Download the sample Report @ https://www.pharmaproff.com/request-sample/1209

Many studies have demonstrated role of galectins in the pathogenesis of various diseases including malignant, fibrotic and inflammatory diseases; hence, emerges as an attractive target for the therapeutic of various diseases. Galectin-3 inhibitors has shown positive clinical results for the treatment of acute lymphoblastic leukemia. Thus, providing several opportunities to the companies for the development of galectin-based therapies for the treatment of multiple human diseases.

Get the detailed analysis @ https://www.pharmaproff.com/report/galectin-inhibitor-therapeutics

Galectin Therapeutics Inc. is in the process of developing GR-MD-02 as a galectin-3 inhibitor for the treatment of fibrosis, cancer and plaque psoriasis. It is also being studied in combination with Yervoy and Keytruda, for the treatment of cancer. GlycoMimetics Inc., and Galecto Biotech AB are some other companies having pipeline of galectin inhibitors.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.